首页> 外文期刊>Thrombosis Research: An International Journal on Vascular Obstruction, Hemorrhage and Hemostasis >Oral delivery of chemical conjugates of heparin and deoxycholic acid in aqueous formulation.
【24h】

Oral delivery of chemical conjugates of heparin and deoxycholic acid in aqueous formulation.

机译:在水性制剂中口服递送肝素和脱氧胆酸的化学结合物。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

INTRODUCTION: Heparin, one of the most potent anticoagulants widely used for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE), is currently available to patients only by parental administration. In this study, we propose a new oral delivery system of heparin by conjugating it with deoxycholic acid which reformulated by adding dimethyl sulfoxide to increase its bioavailability. MATERIALS AND METHODS: The chemical conjugates (LMWH-DOCA) of low molecular weight heparin (4.5 kDa) with deoxycholic acid (DOCA) were synthesized by controlling the conjugation ratio. The absorption of LMWH-DOCA after its oral administration was measured by anti-FXa assay according to the conjugation ratio of DOCA, concentration of DMSO solution and dose of LMWH-DOCA, respectively. Furthermore, the incidences of mucosal damage by LMWH-DOCA in 10% DMSO solution were evaluated using H&E staining and SEM. RESULTS: Three kinds of LMWH-DOCA were synthesized according to the DOCA conjugation ratios of LD1, LD2 and LD3, whose anticoagulant activities were 89, 86 and 85 IU/mg, respectively, and the activity of LMWH was 97 IU/mg. LMWH-DOCA was completely dissolved in 10% DMSO solution, and its bioavailability in the oral dose was significantly increased (17.6% for LD2 in 10% DMSO solution) without causing any damages in intestinal tissues. CONCLUSIONS: The chemical conjugate of heparin and DOCA in the soluble state could be efficiently absorbed in the intestine. Therefore, we propose this system as a new strategy of oral heparin delivery for the treatment of patients who are at high risk to DVT and PE.
机译:简介:肝素是最广泛用于治疗和预防深静脉血栓形成(DVT)和肺栓塞(PE)的最有效的抗凝剂之一,目前仅通过父母给药才可用于患者。在这项研究中,我们提出了一种新的肝素口服给药系统,将其与脱氧胆酸共轭,而脱氧胆酸通过添加二甲基亚砜来提高其生物利用度。材料与方法:通过控制共轭比,合成了低分子量肝素(4.5 kDa)与脱氧胆酸(DOCA)的化学共轭物(LMWH-DOCA)。分别根据DOCA的结合率,DMSO溶液的浓度和LMWH-DOCA的剂量,通过抗FXa测定法测量LMWH-DOCA口服后的吸收。此外,使用H&E染色和SEM评估了LMWH-DOCA在10%DMSO溶液中引起的粘膜损伤的发生率。结果:按照DOC1,LD2和LD3的DOCA结合率合成了三种LMWH-DOCA,其抗凝活性分别为89、86和85 IU / mg,LMWH的活性为97 IU / mg。 LMWH-DOCA完全溶解在10%DMSO溶液中,口服剂量的生物利用度显着增加(LD2在10%DMSO溶液中为17.6%),而不会引起肠组织损伤。结论:肝素和DOCA的化学共轭物在可溶状态下可以有效地被肠道吸收。因此,我们建议将该系统作为口服肝素输送的新策略,用于治疗DVT和PE高危患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号